Brian Herst, MD
Ophthalmology · Chicago, ILNPI 1801235734
Payments from drug & device makers
Across 216 payments — averaging $37.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Baxter Healthcare$2K
- Alcon$1K
- Kala Pharmaceuticals, Inc.$589
- Sun Pharmaceutical Industries Inc.$238
- Sight Sciences, Inc.$230
- plus $2K from 22 others
What the payments were for
- Consulting fees$3,27540%
- Food & beverage$4,69058%
- Education$801%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $2,209 |
| Baxter Healthcare | 1 | $1,500 |
| Alcon | 23 | $1,317 |
| Kala Pharmaceuticals, Inc. | 27 | $589 |
| Sun Pharmaceutical Industries Inc. | 12 | $238 |
| Sight Sciences, Inc. | 10 | $230 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $222 |
| Rxsight Inc | 9 | $208 |
| Bausch & Lomb Americas Inc. | 9 | $175 |
| Harrow Eye, LLC | 6 | $169 |
| Amgen(2 entities) | 6 | $141 |
| Novartis | 6 | $127 |
| Aerie Pharmaceuticals, Inc. | 6 | $121 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $114 |
| Glaukos Corporation | 3 | $88 |
| Thea Pharma Inc. | 4 | $83 |
| Eyevance Pharmaceuticals LLC | 5 | $83 |
| Astellas Pharma US Inc | 3 | $77 |
| Biotissue Holdings Inc. | 4 | $70 |
| Shire North American Group Inc | 3 | $65 |
| NEW World Medical,inc. | 4 | $60 |
| Tarsus Pharmaceuticals, Inc. | 2 | $54 |
| Lumibird Medical Inc. | 1 | $31 |
| Oyster Point Pharma, Inc. | 1 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Heidelberg Engineering, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$600
- OZURDEX$475
- Voyager DSLT$136
- INVELTYS$120
- Centurion$108
How this compares
$8,090 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 102 | $59,431 |
| RestasisCyclosporine | 36 | $50,903 |
| XiidraLifitegrast | 23 | $35,607 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $24,554 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 62 | $15,340 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $14,855 |
| RhopressaNetarsudil Mesylate | 20 | $12,922 |
| VyzultaLatanoprostene Bunod | 21 | $12,457 |
| Latanoprost | 698 | $10,813 |
| Alphagan PBrimonidine Tartrate | 19 | $9,636 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $8,451 |
| Brimonidine Tartrate | 189 | $5,848 |
| Travoprost | 28 | $5,548 |
| Timolol Maleate | 232 | $4,458 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 254 | $4,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,209 | $134,825180 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $175 | $48,06444 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $121 | $37,47651 claims |
| AlconSimbrinza | $1,317 | $15,34062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Manjot GillChicago$1.4M
- Amani FawziChicago$864K
- Sarah SunshineChicago$664K
- Jennifer LimChicago$636K
- Dilraj GrewalChicago$543K
- Ahmad ArefChicago$355K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Armin AfsharChicago$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.